fashion -WSS

fashion

author：leisure time 2025-10-02 19:39:50 - browse：1829

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Sen. Bill Cassidy on how to lower drug prices

WSS

House panel to mark up pandemic

Trump seeks lengthy delay of classified docs trial, citing upcoming election

US intelligence assessment says Iran not currently developing nuclear weapons

New chart reveals military’s vast involvement in Operation Warp Speed

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

North Korean leader's powerful sister says warplanes repelled US spy plane

hotspot

fashion

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

With fresh data, a dynamic duo powers Eli Lilly to new heights

BioMarin wins approval for gene therapy to treat hemophilia A

Pfizer's RSV vaccine recommended for approval in Europe

In age of alternative facts, a scholarly course on calling out crap

Reframing the conversation around gain

As demand for Covid shots wanes, Moderna seeks its next success

Reframing the conversation around gain

23andMe had bad news about my health. I wish a person had delivered it

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

explore

How Brent Saunders' Allergan experiment failed

The biotech scorecard for the 2nd quarter: 12 industry events to watch

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Why Titanic fascinates society, still drawing tours to the wreckage

Prosecutors say FTX founder Sam Bankman

What is artificial intelligence? Experts weigh in

explore

knowledge

leisure time

entertainment